EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry
نویسندگان
چکیده
منابع مشابه
EGFR mutation testing in non-small cell lung cancer (NSCLC).
Lung carcinoma is subdivided into small cell carcinoma and non-small cell carcinoma (NSCLC). NSCLC is heterogeneous group of carcinomas and accounts for 70-80% of lung cancer. NSCLC is further divided into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Activating somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor (EGFR) have recently been cha...
متن کاملAscertaining an Appropriate Diagnostic Algorithm Using EGFR Mutation-Specific Antibodies to Detect EGFR Status in Non-Small-Cell Lung Cancer
BACKGROUND Epidermal growth factor receptor (EGFR) mutation status is the most valuable indicator in the screening of non-small-cell lung cancer (NSCLC) patients for tyrosine kinase inhibitor (TKI) therapy. Accurate, rapid and economical methods of detecting EGFR mutations have become important. The use of two mutation-specific antibodies targeting the delE746-A750 mutation in exon 19 and L858R...
متن کاملAnalysis of CEA Expression Level and EGFR Mutation Status in Non-small Cell Lung Cancer
Epidemiological data suggest that the incidence of non-small cell lung cancer (NSCLC) is rapidly rising, and smoking is the leading cause of lung cancer in the world. The traditional therapies for NSCLC mainly include surgery, radiotherapy, chemotherapy etc (Liu et al., 2013; Lu et al., 2013; Yan et al., 2013; Ji et al., 2014; Cui et al., 2014). However, these therapeutic interventions often br...
متن کامل18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer
Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) are a response to EGFR-tyrosine kinase inhibitor. However, a lack of sufficient tumor tissue has been a limitation for determining EGFR mutation status in clinical practice. The objective of this study was to predict EGFR mutation status in NSCLC patients based on a model including maximum standardized uptak...
متن کاملPredictive factors in patients with EGFR mutation-negative non-small cell lung cancer treated with erlotinib
Factors predicting the efficacy of erlotinib treatment in patients with EGFR mutation-negative non-small-cell lung cancer (NSCLC) have not been well studied. This retrospective study investigates whether patient characteristics, such as site of metastasis, can predict the efficacy of erlotinib treatment in NSCLC patients. In total, 53 EGFR mutation-negative NSCLC patients treated with erlotinib...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMC Pulmonary Medicine
سال: 2018
ISSN: 1471-2466
DOI: 10.1186/s12890-018-0706-5